Skip to main content

Market Overview

EyePoint Pharmaceuticals: Q3 Earnings Insights

Share:

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 45.00% year over year to ($0.11), which missed the estimate of ($0.10).

Revenue of $7,489,000 higher by 272.22% year over year, which beat the estimate of $7,250,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: May 06, 2020

Webcast URL: https://edge.media-server.com/mmc/p/wmbgnxa6

Technicals

52-week high: $2.69

52-week low: $0.70

Price action over last quarter: down 30.08%

Company Profile

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed 5 FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

 

Related Articles (EYPT)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com